An Altos Labs rival? Genentech throws its hat into buzzy 'cellular rejuvenation' field
Just a few short months after Altos Labs made its debut flush with $3 billion in cash, a famous CEO and a star-studded scientific team, the cellular rejuvenation biotech may now be seeing the first inklings of a competitor: Genentech.
The large biotech and Roche subsidiary published in Nature Aging last week on cellular rejuvenation. Although it’s still early and the approach faces huge hurdles before reaching humans, this is one of the first times that a large, well-known biotech has shown interest in the field that Altos is trying to pioneer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.